# Study of Tarceva and Targretin in Stage I-II Lung Cancer

> **NCT00125372** · NA · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Carcinoma, Non-small-cell Lung

## Interventions

- **DRUG:** erlotinib (Tarceva) and bexarotene (Targretin)

## Key facts

- **NCT ID:** NCT00125372
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125372, "Study of Tarceva and Targretin in Stage I-II Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00125372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*